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Meta-analytical methods to identify who benefits most from 
treatments: daft, deluded, or deft approach?
David J Fisher,1 James R Carpenter,1,2 Tim P Morris,1 Suzanne C Freeman,1 Jayne F Tierney1 
Identifying which individuals benefit 
most from particular treatments or other 
interventions underpins so-called 
personalised or stratified medicine. 
However, single trials are typically 
underpowered for exploring whether 
participant characteristics, such as age 
or disease severity, determine an 
individual’s response to treatment. 
A meta-analysis of multiple trials, 
particularly one where individual 
participant data (IPD) are available, 
provides greater power to investigate 
interactions between participant 
characteristics (covariates) and 
treatment effects. We use a published 
IPD meta-analysis to illustrate three 
broad approaches used for testing such 
interactions. Based on another 
systematic review of recently published 
IPD meta-analyses, we also show that all 
three approaches can be applied to 
aggregate data as well as IPD. We also 
summarise which methods of analysing 
and presenting interactions are in 
current use, and describe their 
advantages and disadvantages. We 
recommend that testing for interactions 
using within-trials information alone 
(the deft approach) becomes standard 
practice, alongside graphical 
presentation that directly visualises this.
Meta-analysis of participant level treatment-covariate 
interactions raises additional complications that do not 
affect either standard meta-analysis or single trial inter-
action analysis alone. These complications are often 
overlooked by reviewers. The issues are independent of 
other aspects of meta-analysis, such as the choice of 
one stage or two stage model fitting, or whether aggre-
gate data or individual participant data (IPD)1  is used. 
The three titular approaches discussed in this paper are 
derived from two independent quantities referred to in 
recent IPD literature as across-trial and within-trial 
interactions.2 3  We have used three descriptive terms to 
be memorable and to avoid ambiguity. “Daft” (meaning 
absurd or preposterous) refers to estimation of the 
across-trial interaction alone. “Deluded” (meaning mis-
leading or deceiving) refers to an estimation of both the 
across-trial and within-trial interactions combined. 
“Deft” (demonstrating skill or cleverness) refers to esti-
mation of the within-trial interaction alone. As their 
monikers suggest, daft and (to a lesser but non- 
negligible extent) deluded approaches are at risk of 
bias4—the extent of which is typically unknown—
whereas deft approaches are not.
How to analyse and present participant level 
interactions data from a meta-analysis: daft, 
deluded, or deft approach
Our illustrative example is a systematic review and IPD 
meta-analysis relating to the care of patients with acute 
stroke, which compared a strategy of early supported 
hospital discharge (ESD) to conventional hospital ser-
vices and discharge arrangements.5  ESD reduced the 
mean duration of initial hospital stay. The authors 
investigated whether this effect varied according to 
whether a participant had a carer present—that is, 
whether there was an interaction between treatment 
and presence of a carer. Here, we describe the results 
from this published IPD meta-analysis using three 
approaches we previously identified.2
Daft approach (across-trial interaction alone)
This approach can be visualised by plotting the mean 
difference in the length of hospital stay (ESD v standard 
care) for each trial against the proportion of trial partic-
ipants who had a carer present. Fitting a meta- 
regression6  to the data points, we find that as the 
Summary pointS
Meta-analysis is often the only way to reliably detect whether treatment benefit 
differs between groups of participants—that is, to detect interactions between 
treatment efficacy and participant characteristics
Of three general approaches, we advocate the deft approach, which avoids the risk 
of ecological bias over the deluded and daft approaches, which do not
A systematic review of recently published meta-analyses of individual participant 
data shows that 89% of interaction analyses either used a deluded method (23%), 
or did not report sufficient details (66%) to tell which approach had been used. 
Further, graphical presentation often hindered appreciation of key data features
These findings indicate poor appreciation of analysis and reporting issues 
surrounding interactions in the research community
Where suitable data were reported in published systematic reviews, reanalysis 
showed that use of the different approaches can yield inconsistent results
Testing for interactions using deft methods, and using a graphical presentation that 
directly visualises this, should become standard practice
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proportion of trial participants with a carer present 
increases, the benefit of ESD decreases (P<0.001, web 
fig 1). This analysis focuses solely on how the overall 
effect of ESD varies across trials with different propor-
tions of carers present, relying on an aggregated sum-
mary of the carer information for each trial rather than 
considering whether the effect for an individual partic-
ipant varies according to the presence of a carer. Such 
an analysis is easily confounded and is at risk of ecolog-
ical bias, whereby interactions at the aggregate (or “eco-
logical”) level might not reflect the true interaction at 
the individual participant level.4 Given the available 
data, this is a daft approach.
Deluded approach (within-trial and across-trial 
interactions combined)
This approach is presented in figure 1 . The left panel 
shows an attempt to make better use of the data by car-
rying out a meta-analysis within the subgroup of partic-
ipants who had a carer present, and another in those 
who did not. The right panel shows a simpler  alternative 
presentation of this type of analysis that is often seen in 
the literature. The interaction test compares the treat-
ment effects in the two carer subgroup level meta-anal-
yses, but can also be extended to explore trends in 
effect across more than two ordered categories, such as 
stage of disease. As in the original review,5  this 
approach suggests that the presence of a carer does not 
modify the effect of ESD (P=0.39). However, consider 
how the data is actually being used: trial data is split 
into participant subgroups, treatment effects are com-
bined within these subgroups, and are then compared 
across subgroups. This process combines within-trial 
and across-trial interaction estimates.3 The analysis is 
again subject to ecological bias, although the addition 
of across-trial information can provide a gain in power. 
How the treatment effect varies at the individual parti-
cipant level (that is, the within-trial interaction) could be 
exaggerated or masked by the across-trial interaction; we 
are at risk of being deluded. In the large Montreal trial,w87 
all participants had a carer, and hence this trial can 
 contribute only an across-trial interaction (web fig).
Deft approach (within-trial interaction alone)
This approach adheres to the underlying principles of 
meta-analysis by assessing the effect of interest as mea-
sured within each relevant trial. The left panel in 
 figure 2  shows the same data as those in figure 1 , but 
 rearranged so as to demonstrate this approach. We test 
for an association between the effect of ESD and pres-
ence of a carer within each trial, instead of testing for an 
association across carer subgroups. These interactions, 
interpretable as the difference in treatment effect for an 
individual participant with a carer present compared to 
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Fig 1 | Use of a deluded approach to analyse and present interactions in meta-analysis , illustrating how the effect of an 
early supported hospital discharge (ESD) strategy might vary by whether a carer is present.5 Left panel presents the effect 
of ESD for each subgroup within each trial, but ordered by subgroup; and right panel presents just the meta-analysed 
effects for each subgroup. The difference between the effects in right panel gives a deluded analysis (mean difference of 
2.23, 95% confidence interval −2.82 to 7.28, P=0.39). Sizing of squares are in proportion to the inverse of the variance of 
the estimates. Note that the subgroup meta-analysis estimates do not match exactly those originally reported, because 
we used a fixed effect model for simplicity, rather than the random-effects model used by the original authors. See also 
web appendix A3 for references of studies and appendix B2 for details of statistical reanalysis
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one without, can be combined and presented by use of 
standard meta-analytical techniques (fig 2, right 
panel).7 In this case, the results show that having a 
carer present increases the effect of ESD on duration of 
hospital stay relative to standard care (P=0.077). The 
right panel in figure 2, however, also shows some visual 
evidence of heterogeneity (confirmed statistically 
(I2=45%)) among the interaction estimates, suggesting 
that presence of a carer might not be a wholly reliable 
indicator of ESD efficacy. Appropriately, the Montreal 
trial is not included in this deft analysis, because a 
within-trial interaction is not estimable.
Systematic literature review of published interactions 
between treatment effects and participant level 
covariates
Having highlighted what is at stake, we present the 
results of our systematic review of the literature. We 
searched Medline (2011-14) for IPD meta-analyses of 
treatment efficacy that included at least one investiga-
tion of interaction between treatment and a partici-
pant level covariate (web appendix A). Our search 
returned 184 unique results, of which 80 were eligible. 
However, one ineligible study cited two additional IPD 
meta- analyses, giving a total of 82 eligible results. 
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Fig 2 | Use of a deft approach to analyse and present interactions in meta-analysis , illustrating how the effect of an early 
supported hospital discharge (ESD) strategy might vary by whether a carer is present.5 The left panel again presents the 
effect of ESD for each subgroup within each trial, but now ordered by trial. The right panel shows the interactions between 
the effect of ESD and presence of a carer for each trial, along with a meta-analysis of the interaction estimates (mean 
difference –6.64, 95% confidence interval –13.65 to 0.71, P=0.77; heterogeneity of interaction estimates: Q=12.8, df=7, 
I2=45%). Daft and deluded interaction estimates are presented alongside for comparison. Squares are used to depict 
treatment effect and circles the interaction effects, with sizing in proportion to the inverse of the variance of the 
estimates
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Table 1 summarises the analysis and presentation 
methods used.
Efforts to advocate a deft approach2 9 (2% of analyses) 
seem to have been largely unheeded, while the deluded 
approach remains popular (23% of analyses). Encour-
agingly, no daft analyses were explicitly reported. How-
ever, in our sample, the majority of reviews (66% of 
analyses) provided insufficient information to identify 
whether a daft, deluded, or deft analysis was carried 
out. This includes both so-called one stage modelling 
approaches (83% of insufficiently described analy-
ses),10 which could be either deludedordeft,2 3  and other 
commonly used but deluded approaches.5 10  Given that 
such results might be used to inform clinical practice, 
this lack of detail is disturbing.11
The majority of reviews (56% of 82) tested for interac-
tion exclusively by calculating the treatment difference 
between just two participant level subgroups, even 
where the underlying data were continuous or ordinal. 
Such collapsing of data is known to be suboptimal, 
both in terms of power and bias, as well as biologically 
implausible.12  Considering the low power inherent in 
interaction testing, this suggests that the analysis of 
interactions could be better planned.13
In our sample, other than presenting no plot at all 
(34% of reviews), the most common presentational 
approach (43%) by far was to present summary treat-
ment effects within each covariate subgroup (fig 1 , right 
panel). As illustrated above, this approach invites read-
ers to combine within-trial and across-trial interaction 
estimates, potentially deluding them about the strength 
of the evidence. A minority of reviews (9%) expanded 
on this, presenting data by trial within each subgroup 
(fig 1, left panel). This approach has more to commend 
it, because more information is displayed; indeed, it 
provides sufficient data to allow the reanalyses reported 
in the next section. 
Nevertheless, we prefer that treatment effects by sub-
group (fig 2 , left panel) or the resulting interactions (fig 2, 
right panel) are plotted within each trial, because this 
corresponds more directly with a deft analysis. Disap-
pointingly, only 2% of reviews adopted such an 
approachw19, w55 by presenting within-trial interactions 
and meta-analyses of these interactions together in a for-
est plot (fig 2, right panel). Two further reviewsw54, w68 
used a deluded approach primarily, but stated an inten-
tion to carry out an additional deft analysis for sensitivity 
(see footnotes to table 1 ).8
reanalysis of published data from systematic literature 
review 
Six meta-analyses from our review5, w21, w28, w38, w47, w61 
presented sufficient data to allow reanalysis of 31 inter-
actions, providing useful insight into the implications 
of using the three approaches. This reanalysis (web 
appendix B) is itself a demonstration that aggregate 
data, albeit in this case derived from IPD, can be 
 analysed by any approach. Our results suggest that, in 
practice, only deluded or deft analyses are used. How-
ever, deluded analyses combine information from daft 
and deft analyses, which we found to be poorly cor-
related (fig 2), demonstrating why a deluded analysis 
might be misleading. In practice, we found deluded 
analyses were more likely to be significant at the 5% 
level than deft analyses (16% v 6%).
We next made a descriptive assessment of levels of 
agreement between effect estimates from deluded and 
deft analyses.14  Our results (fig 4 ) show that deluded 
analysis did not result in a systematic bias in effect size, 
Table 1 | Systematic literature review: presentation and analysis of treatment-covariate interactions
Primary method of analysis
No (%) of 
meta-analyses
Primary method of presentation
Forest plot by 
subgroup only
Forest plot by 
subgroup and trial
Forest plot of 
interactions
Kaplan-Meier 
plots by subgroup
Line plots (for 
continuous covariates) No plot
Total No (%) of meta-analyses 82 (100) 35 (43) 7 (9) 2 (2) 7 (9) 3 (4) 28 (34)
Deft* 2 (2) — — — — — 2 (2)
Deluded* 19 (23) 13 (16) § 3 (4) — — — 3 (4)
Unclear† 54 (66) 20 (24) 3 (4) 2 (2)¶ 6 (7) 2 (2) 21 (26)
Descriptive only‡ 7 (9) 2 (2) 1 (1) — 1 (1) 1 (1) 2 (2)
Primary methods of analysis and presentation were considered to be those either described as such, or appearing first in the article. Generally, only one method was used per review; the 
exceptions are detailed below.
*A statistical test was used that satisfies the definition of a deft or deluded approach as given in this article, including one stage models. 
†A statistical test was done (including one stage model fitting), but insufficient details were given for it to be definitely described as a daft, deluded, or deft analysis.
‡Results were presented by subgroup, but no statistical tests of interaction were reported or implied.
§Two reviewsw54, w68 also stated that a deft analysis might be used for sensitivity; one did in fact present such a plot in an additional publication (see ¶).
¶Another revieww68 also presented a forest plot of interactions in their Cochrane Database review,8 but not in their peer reviewed journal article.
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reanalyses (see web appendix B) of treatment-covariate 
interactions against the corresponding daft reanalyses. 
Added lines are at P=0.1; arguably a suitable level of 
significance for an interaction test for which a trial was not 
powered
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although any individual analysis could differ from its 
deft equivalent by up to 20% in either direction. There 
seemed to be two distinct patterns of discrepancy. 
Firstly, the effect size as estimated from the deluded 
analysis could be substantially larger than that from the 
deft analysis, as also demonstrated by our illustrative 
example (fig 2 ). This is likely a result of differences in 
the distribution of participant characteristics across tri-
als,15 inducing a strong daft effect that confounded the 
deluded result. Secondly, the effect size as estimated 
from the deluded analysis could be comparable to that 
from the deft analysis, except that the deft analysis 
might not reach significance but the deluded analysis 
does, by virtue of gaining power from the daft.
recommendations for analysis and presentation of 
interaction data
Poor reporting and presentation, particularly when com-
bined with inappropriate methods, is a key shortcoming 
of interaction analyses. Given that a deft analysis is at the 
least risk of bias, and can be clearly presented and read-
ily interpreted, it should be the preferred approach for 
assessing participant level interactions aimed at influ-
encing clinical practice. This can be achieved (eg, using 
Stata16 ) with either IPD17  or aggregate data; although the 
aggregate data requires treatment effects to be reported 
by subgroup or similar.18 If these are not available, but 
interaction analysis remains an important component of 
the research project, we recommend requesting suitable 
aggregate data, or the full IPD, from the trial  investigators. 
Going forward, we recommend that trial investigators 
routinely report all by-subgroup effect estimates gener-
ated by trial analyses.
Plotting treatment effects in each participant group 
for each trial alongside a forest plot of the within-trial 
interactions (fig 2 ) focuses attention on those effects 
and their association with the interaction estimates. 
Use of circles instead of squares for the interaction esti-
mates2  (fig 2 , right panel) helps distinguish such plots 
from those of main treatment effects. If space is limited, 
the summary within-trial interaction effect2  for a series 
of covariates can be displayed on one forest plot—for 
example, figure 3 in reference 17 , which may be 
 accompanied by a more detailed plot for those analyses 
meriting further exploration—for example, web figure 2 
in reference 17 ). Further detail, to provide greater clar-
ity for what is currently a less familiar approach, could 
be provided by a plot similar to the entirety of figure 2.
Although a forest plot of treatment effects by covari-
ate subgroup (eg, fig 1 , right panel) might be considered 
clinically useful, the visual and statistical comparison 
of such effects in the meta-analysis context remains 
deluded. This could invite claims regarding the efficacy 
of treatments for particular participant subgroups with-
out appropriate regard to a test for interaction.19  Many 
reviewers continue to use deluded analysis methods—
possibly because they have been widely used by well 
respected groups for many years10—which risks mis-
leading conclusions and potentially inappropriate clin-
ical recommendations. 
However, within-trial (deft) identification of interac-
tions is relatively rare,2  probably in part because of low 
power. If the across-trial (daft) interaction provides 
greater power,15 then both sources combined (deluded) 
could substantially improve the power of the interac-
tion estimate over within-trial information alone, albeit 
with an increased risk of ecological bias. This may be 
particularly true where some trials, such as Montrealw87 
in our illustrative example,5 only contribute data to one 
subgroup and therefore cannot be included in a deft 
analysis. Our reanalysis of the published data suggests 
that ecological bias might be present in deluded analy-
ses even when based on a set of trials identical to that 
used in the deft (data not shown). Hence, although a 
deluded approach might have a role in exploratory 
analyses or hypothesis generation, we strongly recom-
mend that this intention be made explicit. Moreover, in 
such cases, within-trial, across-trial, and combined 
interactions should be presented separately so that 
readers will not be deluded. Rather, they can make their 
own judgments about the usefulness or otherwise of the 
daft estimate.
The two stage approach we recommend here has 
been criticised for being overly simple, inflexible, and 
possibly underpowered. Certainly, one stage models 
fitted to the entire dataset simultaneously allow for 
greater complexity; but an assessment of their relative 
power is confounded by their ability to produce either 
deluded or deft results depending on the separation of 
within-trial and across-trial effects.2 3  Unfortunately, we 
have found that the details required are rarely provided 
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Fig 4 | Bland-Altman14 plot showing level of agreement 
between treatment-covariate interactions from deluded 
and deft analyses. Thirty one interactions were reanalysed, 
but only 26 with outcomes measured by hazard ratios or 
odds ratios were plotted. The remaining five interactions, 
including our illustrative example, could not be included 
since their outcomes were measured by mean differences 
and were hence incompatible. Treatment-covariate 
interactions (measured on the log scale) might have a 
positive or a negative sign, but in this plot they have all 
been set to negative. Hence, differences in interaction 
effects below the zero line represent cases where a 
deluded analysis gives a result in the same direction as, 
but more extreme than, the equivalent deft analysis, and 
vice versa. Shaded area=Bland-Altman 95% limits of 
agreement14; solid line represents mean difference (bias); 
dashed lines are 95% confidence intervals around the 
mean difference
ReseaRch Methods and RepoRting
See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
to judge whether models have been correctly specified 
so as to accomplish this.13  Furthermore, it is not obvi-
ous how best to present graphically the results of a one 
stage model. We would recommend that it be used pri-
marily for inference, while an additional two stage 
model (which can produce only deft results) is used as 
the basis of the forest plot. This approach has previ-
ously been suggested in the context of main treatment 
effects.20
Our example (fig 1 ) shows how to proceed with a 
binary covariate. Categorical participant level covari-
ates, such as disease severity, also featured prominently 
in our literature review. If such covariates have a  natural 
ordering, a deft meta-analysis of within-trial interac-
tions can be carried out assuming a linear trend across 
categories.2  Continuous variables such as age should 
not be categorised for statistical testing, because this 
loses power; worse, the choice of categorisation might 
affect the magnitude and statistical significance of the 
results.12 In the case of categorical covariates where a 
linear trend is not an appropriate assumption, it is pos-
sible to do a global test of interaction. This simply tests 
for some variation in treatment effect across participant 
subgroups without specifying its nature; but the risk of 
ecological bias in this context is unclear.
Conclusions
Investigating associations between the effects of treat-
ments or other interventions and participant level covari-
ates can help identify who is most likely to benefit, and 
allow treatments to be targeted appropriately. In an era 
when such investigations are increasingly common, deft 
analysis and presentation should be the recommended 
approach for reliably informing clinical practice.
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